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Abstract
Background: Prognostic assessment tools to identify subgroups of patients at risk of persistent low back pain who
may benefit from targeted treatments have been developed and validated in primary care. The IMPaCT Back study
is investigating the effects of introducing and supporting a subgrouping for targeted treatment system in primary
care.
Methods/Design: A prospective, population-based, quality improvement study in one Primary Care Trust in
England with a before and after design. Phases 1 and 3 collect data on current practice, attitudes and behaviour of
health care practitioners, patients’ outcomes and health care costs. Phase 2 introduces and supports the
subgrouping for targeted treatment system, via a multi-component, quality improvement intervention that includes
educational courses and outreach visits led by opinion leaders, audit/feedback, mentoring and organisational
support to embed the subgrouping tools within IT and clinical management systems.
We aim to recruit 1000 low back pain patients aged 18 years and over consulting 7 GP practices within one Pri-
mary Care Trust in England, UK. The study includes GPs in participating practices and physiotherapists in associated
services. The primary objective is to determine the effect of the subgrouping for targeted treatment system on
back pain related disability and catastrophising at 2 and 6 months, comparing data from phase 1 with phase 3. Key
secondary objectives are to determine the impact on:
a) GPs’ and physiotherapists’ attitudes and behaviour regarding low back pain;
b) The process of care that patients receive;
c) The cost-effectiveness and sustainability of the new clinical system.
Discussion: This paper details the rationale, design, methods, planned analysis and operational aspects of the
IMPaCT Back study. We aim to determine whether the new subgrouping for targeted treatment system is
implemented and sustained in primary care, and evaluate its impact on clinical decision-making, patient outcomes
and costs.
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Background
Low back pain (LBP) affects over one third of adults at
any one time, and each year approximately 3.5 million
people in the UK develop back pain [1]. It is the most
common reason for middle-aged people to visit their
general practitioner (GP), with approximately 6-9% of
adults consulting for this condition each year [2].
Although many back pain patients stop consulting their
GP within three months, 60-80% of people still report
pain or disability a year later, and up to 40% of those
who have taken time off work will have future episodes
of work absence [3,4]. The societal cost of work absence
attributable to back pain, together with back pain
related health care utilisation, constitutes a considerable
economic burden. Total back pain related costs in the
UK are estimated to form 1-2% of gross national pro-
duct, [5] with National Health Service (NHS) related
costs alone in the region of £251 million per annum [1].
Most patients with back pain are treated in primary
care, where an estimated 85% will have ‘non-specific’
LBP, for which diagnostic labelling is discouraged, and
treatment is guided by symptoms and the experience
and preferences of individual health care practitioners.
In the UK, referral to physiotherapy is a popular man-
agement option for GPs, with LBP accounting for more
than half of physiotherapists’ workload [6]. Whilst the
focus of primary care treatment is on minimising pain
and disability, previous studies have shown variation in
clinical practice [7] and highlighted the gap between
current practice and best practice recommendations
[6,8-12]. Previous studies have also underlined the chal-
lenge practitioners face in applying best practice at an
individual patient level, their concerns about the need
for specialist advice for those with chronic LBP [13] and
their capacity to identify and address psychological
obstacles to recovery [14].
Patients with poorer physical function and those with
psychological obstacles to recovery such as psychological
distress, negative feelings about their back pain and
increased fear of activity, are more disabled by their
pain and are more likely to have a poor outcome [15].
Despite the plethora of clinical guidelines for the man-
agement of back pain and the call to use a biopsychoso-
cial framework [15], a key challenge is the early
identification of patients at risk of chronicity and subse-
quently preventing such chronicity [16]. Addressing
these factors in primary care at an early stage before
they become entrenched and more difficult to treat
could lead to better long-term outcomes.
Improved patient outcomes have been demonstrated
in some studies where subgrouping has been used to
guide treatment [17,18]. Prognostic assessment tools, in
primary care, to identify subgroups of patients at risk of
persistent LBP and who may benefit from interventions
that target key physical and/or psychological obstacles
to recovery have been developed and validated. The
STarT Back tool [19] is specifically designed for primary
care settings and is a subgrouping tool that classifies
patients into three categories for targeted treatment,
based on the presence of modifiable risk factors for
chronic or recurrent LBP. Three targeted treatments for
patients and training programmes for clinicians have
been developed. A randomised controlled trial (the
STarT Back trial) has tested whether subgrouping for
targeted treatment is better than best current care (pro-
vided by physiotherapists) of non-targeted treatment
[20] addressing the call within recent national guidelines
for further investigation of ‘matching’ or subgrouping
LBP patients to different treatments [15].
The IMPaCT Back study (IMplementation study to
improve Patient Care through Targeted treatment for
Back pain) is a quality improvement study designed to
introduce and support a subgrouping for targeted treat-
ment system within primary care practice, and to study
the effects on patients, practitioners and health care
resource use. Many terms are used to describe the pro-
cess of quality improvement in clinical practice, such as
implementation, knowledge diffusion, transfer and
exchange, and innovation diffusion. Implementation
research is defined as ‘the scientific study of methods to
promote the systematic uptake of research findings and
other evidence-based practices into routine practice, to
improve the quality of health care. It includes the study
of influences on healthcare professional and organisation
behaviour’ [21]. In this paper, we use the term quality
improvement as in the SQUIRE (Standards for Quality
Improvement Reporting Excellence) guidelines [22] in
recognition that this is a process that needs a systematic
and planned approach but that it is also essentially an
applied science, driven by experiential learning so that
interventions can be modified in response to feedback.
Unlike targeting the general public through mass
media campaigns about LBP [23-25] we are targeting
health care practitioners and the health care system
within which they work. Several previous studies have
attempted to change health care practitioner behaviour
for LBP [11,26-31] with mixed results. None have inves-
tigated subgrouping for targeted treatment systems
based on risk identification or provided comprehensive
data on the effect of the quality improvement on practi-
tioners’ attitudes and behaviours, clinical processes of
care, patients’ clinical outcomes and cost-effectiveness.
Study Aims
Working with one Primary Care Trust (PCT) in England,
we will introduce a subgrouping for targeted treatment
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care system for the assessment and management of LBP
patients in primary care and evaluate the effects on
health care practitioner attitudes and behaviour, care
processes, patients’ clinical outcomes through to six
months following their primary care consultation and
cost-effectiveness. Specific objectives are to:
(i) engage GPs, physiotherapists and PCT managers
to deliver the new subgrouping for targeted treat-
ment model of care;
(ii) change GPs’ and physiotherapists’ LBP-related
attitudes and clinical behaviours using the subgroup-
ing for targeted treatment approach;
(iii) improve patients’ clinical outcomes at 2 and 6
months follow-up;
(iv) estimate the cost-effectiveness of the subgroup-
ing approach, addressing NHS and societal interests;
(v) provide evidence for the sustainability of this care
system.
This publication details the rationale, design, the sub-
grouping for targeted treatment system, study methods,




A prospective, population-based, quality improvement
study of before and after design, comprising three phases:
Phase 1: assessment of GPs’ and physiotherapists’ atti-
tudes and behaviours regarding LBP, observation of
usual clinical practice and clinical outcomes of patients
recruited in a 6 month baseline period;
Phase 2: a multi-component, quality improvement
intervention comprising educational courses and out-
reach visits led by opinion leaders, regular audit/feed-
back and mentoring support for participating health
care practitioners in addition to installation of compu-
terised and paper-based systems to support the sub-
grouping for targeted treatment care system in practice;
Phase 3: assessment of GPs’ and physiotherapists’ atti-
tudes and behaviours regarding LBP, observation of clinical
practice and clinical outcomes of patients, recruited in a 12
month period following roll-out of the new care system.
The study design is summarised in Figure 1.
We considered using a clinical trial design with cluster
randomisation at the level of GP practice. However, the
physiotherapy service is PCT based rather than GP prac-
tice based, which would have been likely to lead to con-
tamination of clusters.
Setting
Participants will be recruited from up to 7 GP practices
and their associated physiotherapy services within one
NHS PCT in the county of Cheshire, England, UK. An
NHS PCT is a type of NHS Trust, part of the NHS in
England, that provides primary and community services
or commissions them from other providers, and is
involved in commissioning secondary care [32]. There
are approximately 152 PCTs in England.
Ethical review
Favourable ethical opinion was obtained from the Che-
shire Local NHS Research Ethics Committee (Study
number: 07/H1017/143).
Independent monitoring
A steering committee with an independent chair and lay
representation is monitoring the study’s progress.
Participants
Health care practitioners (GPs and physiotherapists) and
patients who consult them with LBP are considered par-
ticipants in this study.
Health care practitioners’ eligibility criteria
All practising GPs at each participating practice and phy-
siotherapists within the associated physiotherapy services
receiving LBP referrals from the participating GP practices
are eligible for the study. We will select which GP prac-
tices within the PCT to invite in order to ensure a breadth
of practice settings (urban/semi-rural/rural) and size
(small/medium/large). General practices and physiother-
apy services are invited to participate following presenta-
tions by the study team at meetings of their practice and
physiotherapy staff. Strategies to facilitate participation of
general practices and physiotherapy services in the study
include continuing professional development activities,
receiving guidance and feedback on their practice, and the
provision of up to date knowledge, skills and tools to sup-
port their management of LBP patients.
Patients’ eligibility criteria
Male and female adults aged 18 years or over, consulting
one of the participating GP practices with non-specific
LBP (with or without leg pain). Participants must under-
stand English to a level where they can read the study
information leaflet and study questionnaires. Exclusions
are those with “red flags” (indicative of possible serious
spinal pathology such as cauda equina, inflammatory
arthritis, malignancy, infection, fracture); pregnancy-
related LBP; conditions which might exclude the patient
from physiotherapy treatment (e.g. serious co-morbidity,
recent major surgery), patients already receiving phy-
siotherapy treatment for this episode of LBP.
The procedures for recruitment, assessment and treat-
ment are summarised below for each phase of the
IMPaCT Back study.
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Phase 1: Observation of usual clinical practice and
patients’ outcomes
We will collect data on health care practitioners’ back
pain-related attitudes and behaviours, patients’ clinical
outcomes and health care resource use before the intro-
duction of the new subgrouping for targeted treatment
system. Data collection in phase 1 will consist of:
a) Health care practitioners’ attitudes and behaviour and
care processes
Attitudes and reported behaviour: We will conduct a
questionnaire survey of participating GPs and phy-
siotherapists to describe their attitudes and beliefs about
back pain and its management, and their reported clini-
cal behaviour relating to two clinical case vignettes
developed from real patients with LBP. The question-
naire and case vignettes have been adapted from a pre-
vious national survey of GPs and physiotherapists [7].
The self-report questionnaire will include key demo-
graphic and clinical experience questions, a measure of
beliefs and attitudes towards LBP, the Pain Attitudes
and Beliefs Scale (PABS) [33,34], and a measure of self-
confidence in managing LBP patients [35]. Full details
of the contents of the questionnaire are provided in
Table 1.
Care processes and actual clinical behaviour: We will
collect data on health care practitioners’ actual clinical
behaviour from anonymised GP medical record reviews
and physiotherapy case report forms, for patients who
consent to the study team accessing their medical
records. We aim to collect data on primary care consul-
tations, ordering of diagnostic tests (radiographs, MRI
and CT scans), prescribed medications, referrals to
other professionals or services and issuing of sickness
certificates. Additional data from physiotherapy case
report forms will include the physiotherapist’s view of
the patient’s key problems and targets for treatment, the
treatment approaches used, the advice given and the
number and length of treatment sessions.
b) Patients’ clinical outcomes
A consecutive sample of patients consulting with LBP at
each participating practice will be recruited in phase 1
for a period of up to 6 months. As each patient consults
with LBP at one of the participating GP practices and is
assessed, if their GP enters a previously validated back
pain Read Code [2] to indicate the reason for consulta-
tion as non-specific LBP, a “pop-up” computer prompt
will remind them that the patient is eligible to be invited
to participate in the IMPaCT Back study. The GP will
inform the patient about the study and ask them if they
are willing to receive further information by post. On
the same computer pop-up screen the GP will record
whether the patient is willing to receive further informa-
tion about the study, in addition to recording their own
clinical impression of the patient’s risk of poor outcome
(low, medium or high risk of poor outcome). The GP
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Figure 1 Summary of IMPaCT Back study design
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if they consider the patient not eligible for the study. In
phase 1, all patients will receive usual primary care, with
referral to other services (including physiotherapy) as
usual. There will be no subgrouping for targeted treat-
ment in phase 1, or any specific training or additional
resources for assessing and managing LBP patients.
Names and addresses of eligible patients will be
extracted weekly from the GP practices’ electronic data-
bases. These patients will be sent a letter inviting them
to participate in the IMPaCT Back study, an information
leaflet and a baseline questionnaire, with a pre-paid
return envelope. Participants will be asked to record
whether they are willing to be contacted again with fol-
low-up questionnaires at 2 and 6 months, and whether
they give permission for their medical records to be
reviewed. Figure 2 provides a summary of the patient
recruitment and follow-up procedures. The patient
questionnaire will collect data across the key domains
recommended for LBP studies i.e. back specific function,
generic health status, pain, psychological distress, work
disability and patient satisfaction [36]. Patient outcome
measures are summarised in Table 2. As the main focus
is the secondary prevention of long-term disability due
to LBP, the primary clinical outcomes are change in the
key physical and psychological risk factors for chroni-
city: back-related disability (Roland-Morris Disability
Questionnaire (RMDQ) [37]) and catastrophising (sub-
scale from the Coping Strategies Questionnaire [38]) at
6 months.
c) Outcomes for the estimation of cost-effectiveness
Recent UK guidelines for the appraisal of cost-effective-
ness require changes in health-related quality of life to be
based on public preferences using a choice-based method
[39]. The EuroQol EQ-5D, a preference-based measure
of health status, meets these requirements [40]. The EQ-
5D will be collected via the patients’ self-report question-
naires at baseline, 2 months and 6 months. Health care
resource use data will be collected through a combina-
tion of medical record reviews and the 6 month self-
report questionnaire. Data collection will focus on key
cost drivers including hospital attendances (inpatient
stays, outpatient appointments and any other hospital
visits to health care practitioners) within the NHS and
private practice, consultations with NHS primary health
care providers (e.g. general practitioner, practice nurse),
prescribed medications, and over-the-counter treatments.
Unit costs assigned to these resources will be obtained
from published sources reflecting UK national averages.
Across all cost components, data will be collected in a
disaggregated format that will enable us to estimate,
separately, back pain-related costs and costs for ‘other’
health problems [41]. To address the societal costs of
LBP, beyond those directly applicable to health care pro-
vision, data regarding employment status and work
absence will also be collected.
For those participants that have given permission for
their medical records to be reviewed, data will be col-
lected in order to gain further insight into the referral
patterns and behaviours of GPs and the self-reported
secondary care episodes reported in the 6 month ques-
tionnaire. The medical record data will also allow us to
assess the validity of responses to some of the resource
use questions within the 6 month questionnaire.
Phase 2: The subgrouping for targeted treatment system
and the quality improvement interventions
In phase 2 we will introduce new care systems within
the GP practices and physiotherapy services, using a
multi-component quality improvement intervention, to
train and support participating health care practitioners
to use a new subgrouping for targeted treatment system
for LBP patients. Details of the subgrouping tools (19)
and the subgrouping for targeted treatment system (20)
are already available. Briefly, the key features are:
i) subgrouping tools (simple, electronic and paper-
based versions) that classify patients as at low, med-
ium or high risk of poor outcome, to help guide
clinical decision-making about treatment and
onward referral [19];
ii) subgrouping patients on the basis of potentially
modifiable risk factors for chronicity;
Table 1 Contents of Health Care Practitioner Questionnaire
Domain Outcome Measures Study
Phase
Clinical experience Length of time qualified 1
Post-graduate training 1,2,3
Self-confidence Self-confidence in managing back pain patients [35] 1,2,3
Beliefs and attitudes Pain Attitudes and Beliefs Scale (PABS) [33,34] 1,2,3
Reported clinical
behaviour
Clinical case vignettes of patients with non-specific low back pain with items relating to investigations,
referrals, advice and medication
1,2,3
Changes in management of low back pain following best practice updates/training programme 2,3
Education Future learning needs 2,3
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iii) targeted treatments in primary care for those
classified at low, medium and high risk of chronicity.
Within the GP consultation, the targeted treatments
include a minimal intervention delivered by GPs (for
those patients at low risk of poor outcome), or refer-
ral to primary care physiotherapists (for those at
medium and high risk of poor outcome). Within the
physiotherapy consultation, the targeted treatments
Patient consults GP with low back pain.
GP enters Read Code on clinical computer
Screen prompt 
appears
Weekly consultation data download
Patient receives invite, 
information, questionnaire 
and consent to follow-up
Patient medical record review






questionnaire but does 
not consent to follow-up
Patient does not return 
questionnaire
Postal follow-up





GP gives patient information about the study and 
continues with usual care (phase 1)
or
GP uses the subgrouping tool, gives best care advice 
and refers to physiotherapy if indicated (phase 3)
Physiotherapy subgrouping
and targeted intervention 
(phase 3)
Figure 2 Flow chart of IMPaCT Back study patient recruitment and follow-up
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include a minimal intervention delivered by phy-
siotherapists (for those patients at low risk of poor
outcome at the time of physiotherapy consultation),
the use of physical approaches for pain relief and
physical function (for those at medium risk), and
additional cognitive-behavioural approaches to tackle
psychological obstacles to recovery (for those at high
risk),
iv) multi-component, quality improvement interven-
tions including educational courses and outreach vis-
its led by opinion leaders, regular audit/feedback and
mentoring support for GPs and physiotherapists in
addition to organisational support to embed the sub-
grouping tools within existing IT and clinical man-
agement systems.
The sub-grouping tools and targeted treatment
approaches
Two versions of a previously developed and validated
subgrouping tool for use in primary care [19] will be
used. The tools include key physical and psychological
predictors of outcome in LBP. A 6-item computer-based
subgrouping tool will be embedded in the EMIS GP
computer system, for use in real-time GP/patient con-
sultations. Following completion, patients are cate-
gorised as either at low (a score of 2 or less) or high (a
score of 3 or more) risk of poor outcome and a recom-
mendation is made about whether or not a referral to
physiotherapy is likely to be most appropriate. Patients
classified as at low risk of poor outcome are recom-
mended to receive best primary care advice and man-
agement by the GP, to include a screen for red flags,
reassurance about their good prognosis, the benign nat-
ure of their pain, and simple messages and advice about
pain relief, appropriate physical activity levels, return to
normal activity (including work), avoiding bed rest,
appropriate use of pain relieving modalities and the role
of further investigations. To reinforce these key mes-
sages, a brief information sheet will be given. No
onward referral to other services is recommended
although patients will be advised to re-consult if symp-
toms persist. Patients at high risk of poor outcome are
recommended to be referred to physiotherapy. The GP
Table 2 Outcome Measures for Patients
Domain Outcome Measures Time Point
(months)
Primary Back Pain Disability Roland and Morris Disability Questionnaire [37] 0, 2, 6
Catastrophising Catastrophising (from Coping Strategies Questionnaire) [38] 0, 2, 6
Secondary Kinesiophobia Tampa Scale Kinesiophobia [53] 0, 6
Bothersomeness Bothersomeness [2] 0, 2, 6
Anxiety/depression Hospital Anxiety and Depression Scale [54] 0, 6
Self-efficacy Pain Self-Efficacy Questionnaire [55] 0, 6
Illness perceptions Musculoskeletal Illness Perceptions Questionnaire [56] 0, 2, 6
Health-related quality of
life
Short Form 12 (version 2) [57] 0, 2, 6
Individualised Goal Scaling [58] 0, 2, 6
Global change Compared to symptoms at baseline 2,6




Pain elsewhere Other body region pain(s) 0
Preference-based health
utility
EQ-5D [60] 0, 2, 6
Employment details Current employment status 0,6
Current/most recent job title 0,6
Work loss due back problem 0,6
Work performance 0,6
Patient satisfaction With information received 2,6
With care received 2,6
Rating of overall results of care 2,6
Health care resource use Primary care consultations 6
Secondary care attendances (NHS and private) 6
Additional health care practitioners (NHS and private) 6
Prescription and over-the-counter medicines and treatments 6
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and patient are then able to use this recommendation in
their decision-making.
A 9-item paper-based version of the subgrouping tool
will be used by physiotherapists to categorise patients as
at low (a score of 3 or less), medium (score of 4 or
more, with fewer than 4 of 5 positive psychological
items) or high risk of poor outcome (score of 4 or
more, with 4 or 5 positive psychological items) and their
subgroup guides the decisions about to treatment. The
tool is presented on one side of A4 and is quick to com-
plete and score. The targeted treatment for those at low
risk of poor outcome mirrors that provided by GPs
(above). For those at medium risk of poor outcome, the
physiotherapist will carry out a comprehensive assess-
ment (including a physical assessment) and negotiate an
individualised treatment plan which specifically targets
the patient’s physical prognostic indicators using evi-
dence-based treatments, including advice and explana-
tion, reassurance, education, exercise and manual
therapy. The number of treatment sessions is flexible,
depending on the needs of the individual patient.
Patients at high risk of poor outcome will receive a
package of care that addresses psychological obstacles to
recovery, in addition to addressing the physical symp-
toms. This consists of a comprehensive biopsychosocial
assessment, including a physical examination and struc-
tured identification of individual obstacles to recovery,
followed by evidence-based management similar to that
described for patients at medium risk of poor outcome
but taking a more focused cognitive-behavioural
approach. Physiotherapists with additional skills drawn
from cognitive-behavioural approaches, to identify and
address psychological distress, and enhanced communi-
cation skills including motivational interviewing techni-
ques and collaborative goal setting will treat these
patients, within the context of an intervention promot-
ing activation, return to normal activities (including
work) and management of future recurrences. There is a
specific focus on the prognostic indicators identified by
the subgrouping tool and the number of treatment ses-
sions is flexible, depending on the needs of the indivi-
dual patient. Where indicated, patients in the medium
and high risk subgroups will be referred onwards for
consideration for investigations or secondary care
interventions.
Multi-component quality improvement intervention
We designed our improvement intervention with the
view that this could, and should, be reflected on and
amended in response to feedback. We reviewed previous
studies of implementation research [42] and specifically
studies aiming to change the behaviour of health care
practitioners in managing LBP [11,26-31,43]. Broadly,
these suggested that practitioner-orientated interventions
(education, academic detailing, reminders, peer feedback,
using educationally influential practitioners) tended to be
more effective than those aimed at organisations or
patients, that active educational interventions (that
include patient examples, practice time, role play, simula-
tion, feedback and review) that directly engage practi-
tioners and multifaceted interventions (combining
elements of both educational and organisational inter-
ventions) are more likely to be effective. Whilst no single
theory of behaviour change was used solely to guide the
intervention [44] we used the data from phase 1 on prac-
titioners’ attitudes, beliefs and confidence in managing
LBP, their treatment orientations from the PABS mea-
sure, baseline reported practice (in response to standar-
dised patient vignettes) and actual practice patterns to
guide the content of the quality improvement
intervention.
Features of the intervention with GP practices and
GPs:
a) Two interactive, practice-based group educational
sessions referred to as ‘Best Practice Updates’ for
GPs, practice managers and practice nurses. Key
messages include diagnostic triage and red flag
assessment, the role of imaging, reassurance and
advice, activity promotion, sickness certification,
return to work and subgrouping for targeted treat-
ment. The subgrouping tool will be introduced and
the recommended targeted treatments discussed.
Discussion on operational aspects of the study will
be included, such as the way in which referral rates
to physiotherapy will be monitored regularly so that
adequate additional support can be provided, if
needed.
b) Embedding the 6-item subgrouping tool in a pop-
up computer screen, within the GP EMIS computer
systems. The electronic tool is activated whenever a
Read Code indicating a non-specific LBP problem is
entered by the GP, reminding the GP about the
study and prompting completion of the subgrouping
tool. A treatment recommendation is automatically
generated to support decision-making. We will also
offer a paper-based version for those GPs who wish
to use it.
c) Educationally influential practitioners (opinion
leaders) suggested by GPs (a consultant rheumatolo-
gist, a GP with special interests (GPSI) in musculos-
keletal problems from the local area) will lead the
Best Practice Updates and the GPSI will take a lead
role in regular communication with each practice.
d) Support for the initiative by key leads within the
organisation (Primary Care Trust), including a lead
GP from the Professionals Executive Committee
(PEC) and the Chair of the PCT. Two of these
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individuals will also provide ongoing support for the
study as members of the Steering Group.
e) Identification of a volunteer ‘link’ GP from each
practice who will be the key person through which
communication about the study will flow. Additional
funding for one clinical session per month will sup-
port this role.
f) Providing each GP Practice with a study pack con-
taining full details about the IMPaCT Back study.
g) Practice based feedback and individual feedback:
Data from phase 1 from GP questionnaires and from
actual practice data will be analysed and key findings
summarised in the Best Practice Updates, comparing
each practice with other participating practices
(anonymised) and comparing each GP with other
GPs within the same practice (not anonymised).
This feedback will be provided in written form in
the Best Practice Updates and used to stimulate peer
discussion about variation in the management of
LBP within each practice.
h) Regular reminders and audit/feedback: we will
provide regular email and written communication
about the study, and about patient recruitment and
use of the subgrouping tool per GP and per practice.
The timing of the reminders and regular feedback is
anticipated to be monthly, but will be guided by
feedback from practices. Reminder stickers about the
study will be made available for those practitioners
who wish to use them for their computer monitors.
i) Patient case-based discussion: depending on pro-
gress and on availability within the practices, we aim
to facilitate further group-based practice meetings to
focus on patient care, using a patient as an example
to show the potential benefits of the sub-grouping
for targeted treatment approach in practice. These
will be led by a physiotherapist to whom the GP
practice refers patients, in order to facilitate patient-
based communication between the practice and the
associated physiotherapy services.
j) Funding support: As well as the additional funding
to support the GP link for the study in each practice
(one clinical session per month), each practice will
also be given £10 per patient identified, in acknowl-
edgement of the small increase in time that it takes
to determine eligibility of patients, to mention the
study to the patient, and to complete the 6-item ver-
sion of the sub-grouping tool.
k) Offers of additional one-to-one or small group
educational meetings: each GP practice and GP will
be offered further contact with a GP lead in the
study team and the study co-ordinator, at regular
intervals throughout phase 2 and 3 to review the use
of sub-grouping tool, the aims of the study, the tar-
geted treatments or any other study related issue.
Features of the intervention with physiotherapy ser-
vices and physiotherapists:
a) Pre-training programme reflective activities/
reading.
b) Stepped education and training programme con-
sisting of a 3 day course for those delivering the tar-
geted treatment for patients classified as at low and
medium risk of poor outcome, including use of the 9-
item subgrouping tool, identifying and managing
patients with physical obstacles to recovery, best
practice for LBP and nerve root pain. A further 6
days of training for those physiotherapists treating
patients at high risk of poor outcome. These addi-
tional 6 days focus on identifying and managing psy-
chological obstacles to recovery and development of
skills through role play, case discussion, audio and
video training materials and simulated patients. The
training programme is supplemented with compre-
hensive manuals but is designed to be as experiential,
skills-based and interactive as possible and includes
discussion of operational aspects of the study. Fund-
ing support to cover backfill for time taken out from
clinical practice for the purposes of training will be
provided and training linked into Continuous Profes-
sional Development plans for individuals through
negotiation with physiotherapy service managers.
c) Individual feedback and review in monthly men-
toring sessions over 12 months following the train-
ing programme, the first six months led by the
training leads and the second six months by senior
physiotherapists and IMPaCT Back participants
within the PCT. This was included as ongoing men-
toring is likely to be the most effective way of conso-
lidating and further developing knowledge, skills and
confidence in the new subgrouping for targeted
treatment system.
d) The subgrouping tool integrated within the phy-
siotherapy assessment for patients with back pain
and the targeted treatment pathways embedded into
the ongoing care pathways for patients.
e) Educationally influential practitioners (opinion
leaders) leading the training and mentoring pro-
gramme, including a consultant clinical psychologist,
consultant physiotherapist specialising in pain man-
agement, an extended scope physiotherapist in a
spinal specialist role, a consultant rheumatologist, a
GPSI and a disability advisor.
f) Support for the initiative by key leads within the
organisation (Primary Care Trust), including the
Chair of the PCT and physiotherapy service
managers.
g) Study pack of all study information and
documentation.
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h) Study newsletter to provide feedback to the parti-
cipating physiotherapists on the progress of the
study.
i) Monthly monitoring of referral rates to phy-
siotherapy and patient waiting times in order to
identify and react promptly with funding support to
increase physiotherapy response to any increase in
demand for the service.
j) Agreed onward care pathways for those patients
felt by physiotherapists to require the services of sec-
ondary care specialists.
Phase 3: Observation of clinical practice and patient
outcomes following implementation of the new care
system
In phase 3, health care practitioners will be able to use
the subgrouping tools and the targeted treatment
approaches for LBP patients as introduced in phase 2.
We will collect data on health care practitioners’ back
pain-related attitudes and behaviours, patients’ clinical
outcomes and health care resource use after the intro-
duction of the new subgrouping for targeted treatment
system.
a) Health care practitioners’ attitudes and behaviour and
care processes
We will repeat the questionnaire survey of participating
GPs and physiotherapists in order to assess changes in
their behaviour, attitudes and beliefs about back pain
and its management after completion of the training
(phase 2) and implementation of the new care systems
(phase 3). We will record their reported behaviour in
response to the same two clinical case vignettes of real
patients with non-specific LBP, and their actual clinical
behaviour, from GP medical record reviews and phy-
siotherapy case report forms (in order to compare them
with the same data from phase 1).
b) Clinical outcomes for patients
A new cohort comprising a consecutive sample of
patients consulting with LBP at each participating prac-
tice will be recruited in phase 3 for a period of 12
months. The longer timescale in phase 3 is deliberately
chosen so that we can study the pattern of use of the
subgrouping for targeted treatment systems over time.
As time progresses, the use of the new tools and tar-
geted treatment may reduce, as practitioners may tend
to go back to previous patterns of practice, and we aim
to monitor this.
When the GP enters a relevant back pain Read Code
into their clinical computer, the pop-up screen will
include the same items as in phase 1 plus the brief (6
item) subgrouping tool, which, once completed, will
yield a targeted treatment recommendation for the GP
and patient to use to inform their decision-making.
Similarly, if the patient is referred to physiotherapy,
their assessment at the first visit with the physiothera-
pist will include use of the subgrouping tool (9 item ver-
sion), which will yield a recommendation about targeted
treatment.
Patient recruitment in phase 3 will be the same as the
procedures described for phase 1. Participants who con-
sent to further contact will receive a follow-up question-
naire at 2 months and 6 months (see figure 2). Those
patients who reconsult in phase 3, who have previously
been invited to take part in phase 1 will not be re-
invited. The same patient outcome measures as phase 1
will be used in phase 3 (see Table 2).
c) Outcomes for the estimation of cost-effectiveness
The collection of cost and outcome data within phase 3
will mirror the approaches in phase 1, i.e. generic mea-
surement of preference-based health-related quality of
life using the EQ-5D and cost components that will
allow for the estimation of back pain-specific and gen-
eric costs associated with the 6 month period following
participants’ initial consultation. In addition to the esti-
mate of cost-effectiveness for the subgrouping approach
(see ‘Data analysis’ section) we will explore whether
there is evidence for sustainability. We anticipate that
improved primary care for patients with LBP will reduce




We aim to involve a minimum of 20 GPs and 20 phy-
siotherapists in the questionnaire surveys of phases 1
and 3, from the participating GP practices and related
physiotherapy services.
Patients
Scoping work in preparation for this study has provided
us with information on rates of consultation and current
referral pathways, by which we can assess the expected
recruitment and determine the power we will have to
detect clinically important changes in patient outcome.
The consultation rate for back pain in local general
practices ranges from 6-10% annually. We aim to invite
7 GP practices (population of approx 45,000 adults aged
18 years or over) from which we expect at least 2,700
LBP consulters per year. Previous research suggests that
approximately 50% of patients will be willing to consent
to completing the questionnaires [45]. Based on these
figures, we anticipate that within the timeline of the
study (across both phases 1 and 3), recruitment of 1000
patients should be feasible.
A difference of 2.5 points in RMDQ [37] change
scores is considered to be a minimum clinically impor-
tant difference [46]. We wish to test the superiority of
the subgrouping for targeted treatment system (phase 3)
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over usual primary care (phase 1) in relation to this 2.5
point difference for those patients in the high and med-
ium risk subgroups, and to test for non-inferiority of the
new care system compared to usual care in the low risk
subgroup. A weighted sample size (based on the time-
line ratio of 1:2 (phase 1: phase 3) of 50 patients (phase
1) and 100 patients (phase 3) is powered at about 80%
to detect a 2.5 point difference, assuming a standard
deviation of 5 and using a 5% two-tailed significance
level. Based on our pilot work, we expect 20% of back
pain patients to be classified as at “high-risk” of poor
outcome, 40% to be at “medium-risk” and 40% at “low-
risk”. Thus, our expected study size of 1000 patients will
enable us to evaluate this clinical difference across the
three risk subgroups, and has 80% power to detect a
‘small’ effect size of about 0.2, equivalent to a mean dif-
ference in RMDQ scores of approximately 1, over the
total study population (taking into account 20% loss to
follow up).
Data analysis
Health care practitioners’ attitudes and behaviour and care
processes
A descriptive summary of the characteristics of the par-
ticipating GPs and physiotherapists will be provided. To
assess differences in health care practitioners’ attitudes
between phase 1 and phase 3, we will compare baseline
mean scores and follow-up mean scores for the self-con-
fidence and PABs scales using matched-analyses techni-
ques (e.g. paired t-test) based on before (phase 1) and
after (phase 3) matching of scores to individual health
care practitioners. The matched-analyses are based on
evaluating the same health care practitioners before and
after; a sensitivity analysis using unmatched approaches
(e.g. unpaired t-test) will be used if the pool of practi-
tioners in phase 3 is not exactly the same as that in
phase 1. As well as providing the best estimate of the
true mean difference, we will also present 95% confi-
dence interval estimates for the difference and give p-
values for the statistical tests performed. Mean changes
in attitudes scores (3 questionnaires: before the quality
improvement interventions, immediately after the qual-
ity improvement interventions and 12 months after the
quality improvement interventions) will also be
described.
Behaviour measures, relating to the two case vignettes,
follow categorical or textual response formats and differ-
ences over time will be described. Health care practi-
tioner behaviour differences between time points will
also be statistically evaluated by comparing data of their
actual clinical practice, e.g. health care consultations,
medication prescriptions, sickness certification and pat-
terns of referral obtained from medical record down-
loads for patients who consent to record reviews and
from physiotherapists’ case report forms. Furthermore,
GP responses to the computer “pop-up” prompt on
‘chronicity risk’ (low; medium; high) and presence of
‘yellow flags’ (no; yes) will be compared to patient ques-
tionnaire responses to the subgrouping tool; the percen-
tage agreements would be expected to be higher after
the quality improvement intervention. These analyses,
based on patient measures, are unmatched and will fol-
low between-group techniques i.e. unpaired t-test, chi
square test and regression methods (as described below
for clinical outcomes).
Clinical outcomes for patients
The primary outcome measures of patient benefit will
be back pain-related disability (measured on the RMDQ
[37] and pain catastrophising (measured on the catastro-
phising subscale of the Coping Strategies questionnaire
[38] at 6 month follow up. Primary analysis of the
patient data will follow the principles of “intention to
treat”, to compare outcomes of patients in phase 1 (pre-
intervention) to those of patients in phase 3 (post-inter-
vention). A “per-protocol” analysis, based on the evalua-
tion of phase 3 patients who were treated with strict
adherence to the subgrouping tool allocation rule (ver-
sus all phase 1 patients) will be carried out as a second-
ary comparison. Estimates of treatment effects, i.e.
comparative outcomes for phase 1 (pre-intervention)
versus phase 3 (post-intervention), with 95% confidence
intervals will be calculated using linear regression (for
numerical outcomes) and logistic regression (for catego-
rical outcomes). Analyses will be carried out both unad-
justed and adjusted for baseline imbalances in certain
variables i.e. age, gender and baseline values of key out-
comes. Statistical adjustment is necessary as this is an
observational, before and after study design, and thus
open to the possibility of confounding bias; adjustment
will ensure parity of key baseline patient characteristics
across phases 1 and 3. Analyses will be carried out at
each patient follow up time point (2 and 6 months) for
primary and secondary outcome measures; the primary
endpoint is 6 months. Analyses will be performed on
available data, and on imputed datasets based on the
method of multiple imputation [47]. We will use
STATA and SPSS for the analyses.
Determining the cost-effectiveness of subgrouping for
targeted treatment
Consideration of cost-effectiveness for any intervention
or policy change requires an incremental approach,
where the focus of analysis is on the joint estimation of
the differences in costs and benefits between the new
process (in this case, phase 3 following the implementa-
tion of subgrouping for targeted treatment systems) and
the standard process (phase 1).
The primary health economic analysis will focus on
the estimation of incremental cost-utility from an NHS
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perspective, in line with current national guidelines [39].
Accordingly, the appropriate cost components for the
base case analysis will consist of all items of back pain-
related resource use within the NHS. Quality-adjusted
life years (QALYs) will be calculated by applying area-
under-the-curve techniques to EQ-5D scores at baseline,
2 months and 6 months [48], assuming linear interpola-
tion between consecutive data collection points. Differ-
ences (phase 3 minus phase 1) in costs and QALYs will
be expressed using the incremental cost-per-QALY
ratio, which provides an estimate of the additional cost
required to gain each additional unit of outcome (1
QALY is interpreted as 1 year spent in full health). The
incremental ratio is merely a point estimate and, there-
fore, it is necessary to address uncertainty. In line with
current recommendations, uncertainty will be addressed
using bootstrapping techniques, cost-effectiveness planes
and acceptability curves [49,50]. As with the clinical out-
comes for patients multiple imputation techniques will
be used to address the issue of incomplete data [47].
To explore the robustness of our findings, a number of
sensitivity analyses will be performed. Data collected as
part of this study will enable other perspectives to be
considered with regard to the estimation of cost-effec-
tiveness. Moving beyond health care resources attributa-
ble to the NHS, a broader ‘societal’ perspective will
incorporate the indirect costs of reduced productivity at
work due to low back pain and also costs incurred within
the private health care sector. A second sensitivity analy-
sis relating to costs will incorporate generic resource use,
rather than just those relating to back pain. With regard
to outcome valuation, an alternative UK-derived prefer-
ence-based measure of health status, the SF-6D, will be
considered [51]. Finally, a complete-case analysis will be
performed to assess the influence of missing data and the
value of adopting multiple imputation methods.
Other analyses
Qualitative research will be nested within the IMPaCT
Back study. Data collection will be via semi-structured
interviews with GPs, physiotherapists and managers.
Qualitative thematic analysis will be aided by the NVivo
data management system and highlight factors that pro-
mote or inhibit the implementation of the new sub-
grouping for targeted treatment system. We are
adopting the Normalisation Process Theory (NPT) as
the conceptual framework to assess the trajectory of the
new subgrouping for targeted treatment system from its
introduction to early implementation and longer-term
maintenance. The NPT [52] focuses on how new prac-
tices are embedded and integrated into their social con-
texts and it allows a systematic and in-depth
understanding of the organisational and social processes
that help complex interventions become embedded.
Discussion
Although it is generally accepted that randomised con-
trolled trials provide the highest level of evidence in
healthcare research, we opted for a pre-post design as
it was more appropriate to study real-life implementa-
tion of a complex intervention, using multiple compo-
nents and targeting multiple outcomes. Using a quasi-
experimental design, the IMPaCT Back study will
introduce, support and evaluate a new care system for
assessing and managing LBP patients in primary care;
subgrouping for targeted treatment. As such, the over-
all evaluation of this quality improvement study will
take account of a wider range of factors than is usually
seen within conventional randomised controlled trials.
This includes health care practitioner attitudes and
behaviour (both reported behaviour and actual beha-
viour), evaluation of clinical care processes, patients’
clinical outcomes and cost-effectiveness of the new
system.
The fluid nature of systems and structures within the
NHS means that health care provision is constantly
changing, and this introduces an added layer of com-
plexity into our analysis of change in this study. There-
fore, given the before/after design of the study, it may
not be possible to definitively conclude that any changes
we see in phase 3 are a direct result of the interventions
from the IMPaCT Back study. We will, therefore, moni-
tor other changes at national level (such as the produc-
tion of new guidelines) and at local level, such as the
commencement of new services for LBP patients within
the PCT and changes in referral rates and waiting lists
for clinical care.
There are limitations to the pre-post study design,
including that any changes seen in phase 3 may be due
to other influences or due to change in GP and phy-
siotherapist behaviour during the study, for reasons
other than the IMPaCT Back study. Potential
Hawthorne effects are likely to be minimised given the
long observational period (6 months in phase 1 and 12
months in phase 3).
This study directly addresses one of the key recom-
mendations from the NICE [15] LBP guidelines: to eval-
uate screening protocols and test their effectiveness in
targeting treatments for patients. If the data favour
phase 3 of the IMPaCT Back study, this will provide
valuable information about brief and feasible ways to
screen patients with LBP in primary care, and improve
their outcome by using information about their risk sta-
tus at consultation.
Foster et al. BMC Musculoskeletal Disorders 2010, 11:186
http://www.biomedcentral.com/1471-2474/11/186
Page 12 of 14
The results of this study will be made available for use
by clinicians, service managers, and commissioners of
care services.
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